The Fast Skin Cancer That Is Not Melanoma: Reading Merkel Cell Carcinoma
Merkel cell carcinoma usually arrives as a small, shiny, painless bump that nobody worries about. It does not look like the dark, irregular mole everyone has been taught to fear. It looks like a cyst, or a pimple that will not settle, on an older person's cheek. Then it grows in weeks. The danger is not that the bump is hidden. It is that the first label it gets is a harmless one, and a harmless label stops the search.
This post walks the disease from the first bump to the follow-up years: why it gets mistaken for something benign, what the AEIOU clues are, how a biopsy proves it, why the lymph nodes are checked even when they feel normal, and what a blood test adds after treatment. It is rare, and most painless bumps are not cancer. But a bump that grows fast deserves a biopsy, not a wait.

The bump that looks like nothing
Most skin cancer education is about melanoma: dark color, uneven border, a mole that changes. Merkel cell carcinoma breaks those rules. The American Cancer Society describes the first sign as a single pink, red, or purple shiny bump that usually does not hurt, typically on sun-exposed skin like the face, neck, arms, or legs, and that tends to grow quickly. Because it is rare and looks like many common skin problems, it is often not suspected at first, and the diagnosis is often made only after a biopsy.
How often is the first impression wrong? In a 2008 study of 195 patients, 56% of Merkel cell lesions were presumed benign at the time of biopsy, and a cyst or acne-like lesion was the single most common impression, at 32% (Heath and colleagues, Journal of the American Academy of Dermatology). 88% were not tender. The median delay from the bump appearing to the biopsy was 3 months, and 63% of lesions had grown rapidly in the 3 months before it.
Ask Healz.
One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.
The vast majority of shiny bumps on older skin really are something else, and men are diagnosed more often than women (per the American Cancer Society). That rarity is exactly why this one gets waved through.
AEIOU: five clues that change the conversation
The same 2008 study gave clinicians a memory aid built from what these tumors looked like at diagnosis:
- Asymptomatic: the bump does not hurt.
- Expanding rapidly: it has grown noticeably in under 3 months.
- Immune suppression: HIV, a blood cancer like chronic lymphocytic leukemia, or anti-rejection drugs after an organ transplant.
- Older than 50.
- UV-exposed site on fair skin, such as the head, neck, or arms.
In that series, 89% of Merkel cell tumors had three or more of these features (also reported by the National Cancer Institute). No single clue means cancer. The value is in the combination: a painless, fast-growing bump on sun-exposed skin in an older or immunosuppressed person is a reason to biopsy now.
The immune clue deserves weight. In the 2008 study, immune suppression was 16-fold over-represented among patients, and chronic lymphocytic leukemia alone more than 30-fold. If you live with a blood cancer or take transplant medications, a new fast-growing skin bump is a different conversation, and it is fair to say so at the appointment. Our guide on basal versus squamous cell skin cancer covers the far more common non-melanoma skin cancers this one gets grouped with.
A virus, or the sun
There are two roads in. Approximately 70% to 80% of US cases are caused by the Merkel cell polyomavirus; the rest are driven by ultraviolet damage, a pathway that is more prominent in places like Australia (per the National Cancer Institute). This is not a footnote. Which road the tumor took changes what a blood test can do after treatment.
What actually proves it: the biopsy and the stains
Merkel cell carcinoma cannot be diagnosed by looking. It takes tissue, and the American Cancer Society notes that an excisional biopsy, removing the whole area, is usually preferred when it can be done.
Several other cancers look similar under the microscope, so the pathologist confirms it with immunohistochemistry, stains that mark specific proteins on the cells. The key one is CK20 (per the American Cancer Society). It is usually paired with TTF-1, because the main look-alike is small cell lung cancer that has spread to the skin: Merkel cell carcinoma is usually CK20-positive and TTF-1-negative, while small cell lung cancer is usually TTF-1-positive (Skin Research and Technology, 2024). The same paper notes these markers are imperfect and some tumors stain atypically, so a borderline case can deserve a second pathology read.
Why the nodes get checked even when they feel normal
This cancer reaches the lymph nodes early. In a review of 982 patients across 18 series, 55.5% had nodal metastases at diagnosis or during follow-up (per the National Cancer Institute). About one-third of patients whose nodes feel and look normal already have microscopic spread, and surgical staging finds positive nodes in at least 25% to 35% of them.
That is why sentinel lymph node biopsy is central to staging. The surgeon finds the first node that drains the tumor site, removes it, and the pathologist checks it for hidden cells. The National Cancer Institute notes it has been suggested as the preferred first step instead of removing all the nodes. Our explainer on what a sentinel node result actually changes shows how to read that report. For imaging, the American Cancer Society notes PET/CT is often preferred, because it checks the whole body in one scan.
Stage is what the outlook hangs on
For people diagnosed between 2015 and 2021, the American Cancer Society reports 5-year relative survival of:
- 79% when the cancer is localized to the skin,
- 66% when it has reached nearby nodes or tissue,
- 31% when it has spread to distant organs,
- 69% across all stages combined.
The National Cancer Institute adds that patients with small local tumors and negative nodes had cause-specific 5-year survival above 90% in one report. That gap, from above 90% to 31%, is the whole argument for the biopsy over the wait.
How it is treated now
Early disease is treated with surgery. Wide local excision is recommended for clinical stage I and II disease, and radiation may be added to the tumor site or nodes (National Cancer Institute).
Advanced disease changed with immunotherapy. Avelumab was FDA-approved for metastatic Merkel cell carcinoma in 2017, pembrolizumab in 2018, and retifanlimab received accelerated approval in 2023 (National Cancer Institute). In a first-line trial of 50 patients, pembrolizumab produced a response in 58%, with complete responses in 30%. These are trial numbers, not promises.
Watching for it to come back, including in the blood
Recurrence is common and early. In the 18-series review, 30.1% of patients had a local recurrence, and in one series 91% of recurrences happened within 2 years (National Cancer Institute). The baseline follow-up is a careful exam of the scar and the nearby nodes, with imaging as symptoms or the care team require.
Here the virus road matters. Many patients with virus-driven tumors make antibodies to the virus's cancer-driving proteins, and those levels can be tracked in the blood. In a 2016 study in the journal Cancer, the antibodies were present in 52% of newly diagnosed patients and in 1% of healthy people. In patients tested over time, a rising level had a 66% positive predictive value for recurrence, and a falling level had a 97% negative predictive value (Paulson and colleagues). The American Cancer Society notes rising levels after treatment can signal a return, and that the test is not used for diagnosis.
Two limits. Patients who test positive at diagnosis had a lower recurrence risk in that study, so those who test negative may need closer imaging instead. And a rising level does not say where the cancer is; imaging still has to find it. One value says little. The slope says a lot.
How Healz reads a bump that someone called a cyst
Merkel cell carcinoma's head start comes from a reasonable first impression: painless, small, probably a cyst. Refusing to stop at that impression is the discipline Healz was built on.
Healz is equipped with root-cause technology. It does not treat "probably a cyst" as the end of the story. It asks the questions a quick look skips: how fast has it grown, is your immune system suppressed, do you take transplant drugs or live with a blood cancer, is it on sun-exposed skin. When the answers line up with the AEIOU pattern, it says so plainly and helps you ask for a biopsy instead of a recheck in three months. It also searches the latest studies and trials for your case, so a question about immunotherapy gets current evidence.
Healz has memory that works on the facts. It pulls the findings out of every upload, from the pathology report and its stains to the sentinel node result and the PET/CT, keeps abnormal values up front, and dates each one. Then it connects them across months. For a seropositive patient, every antibody result lands on one line, so a rise after two falling values is caught as a change, not lost between portals. Your files sit in a private library: private to you, encrypted, never used for ads.
This is Cancer-Trained AI, with everything in one chat, not ten apps. Healz can create a ready document in the chat, such as a PDF of questions about margins, nodes and the antibody test for your next appointment. And when you want specialist eyes on the case, you can bring top oncologists into the same chat for a second opinion.
Frequently asked questions
- What does Merkel cell carcinoma look like?
The American Cancer Society describes a single pink, red, or purple shiny bump that usually does not hurt and tends to grow quickly, most often on sun-exposed skin. It often looks like a cyst or pimple rather than a dark mole. In one study, 56% of tumors were presumed benign at biopsy (Journal of the American Academy of Dermatology, 2008).
- Is Merkel cell carcinoma worse than melanoma?
They are different cancers, and outlook depends on stage. Merkel cell carcinoma is much rarer and reaches the lymph nodes early, with microscopic node spread in about a third of patients whose nodes seem normal (National Cancer Institute). Its 5-year relative survival is 79% when localized and 31% when distant (per the American Cancer Society).
- What does AEIOU stand for in skin cancer?
It is a memory aid for Merkel cell carcinoma: Asymptomatic, Expanding rapidly, Immune suppression, Older than 50, and UV-exposed skin. In the 2008 study that introduced it, 89% of tumors had three or more of these features. No single feature means cancer, but the combination is a reason to biopsy.
- Is there a blood test for Merkel cell carcinoma?
Not for diagnosis; that takes a biopsy. After diagnosis, about half of patients make antibodies to the Merkel cell polyomavirus's cancer proteins, and a falling level had a 97% negative predictive value for recurrence in a 2016 study in Cancer. Patients without these antibodies may need closer imaging follow-up instead.
- Is Merkel cell carcinoma caused by a virus?
Most of the time in the United States, yes. About 70% to 80% of cases are caused by the Merkel cell polyomavirus, and the rest are driven by sun damage (per the National Cancer Institute).
A painless shiny bump is almost never Merkel cell carcinoma. But when it grows in weeks, sits on sun-damaged skin, and belongs to someone older or immunosuppressed, the right move is a biopsy, not a wait. The cancer's whole advantage is the reassuring first label, and the fix is not stopping there.
Written by Healz Team · Filed under Health Insights